CN114306630A - Polypeptide targeting brain tumor, derivative and application thereof - Google Patents
Polypeptide targeting brain tumor, derivative and application thereof Download PDFInfo
- Publication number
- CN114306630A CN114306630A CN202111488756.1A CN202111488756A CN114306630A CN 114306630 A CN114306630 A CN 114306630A CN 202111488756 A CN202111488756 A CN 202111488756A CN 114306630 A CN114306630 A CN 114306630A
- Authority
- CN
- China
- Prior art keywords
- seq
- polypeptide
- modification
- group
- osteocalcin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
Abstract
The invention discloses a polypeptide targeting brain tumor, a derivative and an application thereof, belonging to the field of biological medicine. Specifically discloses an application of polypeptide in preparing brain tumor targeting drugs or detection reagents, wherein the polypeptide is selected from metabolin or osteocalcin; also discloses a derivative thereof, wherein the derivative is a product obtained by modifying the tail end or the side chain of the polypeptide. The polypeptide molecules can enter brain tissues across the blood brain barrier and are combined with brain tumor regions, and a specific targeted delivery means is provided for diagnosis and treatment of brain tumor diseases.
Description
Technical Field
The invention belongs to the field of medical biology, and relates to a polypeptide targeting brain tumor, a derivative and an application thereof.
Background
In the diagnosis and treatment of brain tumor, due to the existence of blood brain barrier, the corresponding medicine is greatly lost in the whole body administration process, and the medicine capable of reaching the brain tumor part is very limited, thereby influencing the diagnosis and treatment of brain tumor diseases. Therefore, it is valuable to find tool molecules that can mediate drug targeting to tumor foci. However, to date, the choice of relevant mediating ligands that can both cross the blood brain barrier and target tumor foci has been very limited. The research on this aspect is slow and the available candidate ligands are also lacking, relative to the enormous clinical demand.
Disclosure of Invention
In view of the bottleneck problems raised in the background art, the present invention aims to provide a brain tumor targeting polypeptide, and derivatives and applications thereof.
The invention provides an application of polypeptide in preparing a drug or a detection reagent for targeting brain tumor;
the polypeptide is selected from the group consisting of a metabolin (Metabolin) or Osteocalcin (Osteocalcin).
Further, the metabolite is selected from the polypeptide shown as SEQ ID NO.1 or SEQ ID NO.3,
YLGASVPSPDPLEPT SEQ ID No.1；
YLYQWLGAPVPYPDPLEPR SEQ ID No.3。
further, osteocalcin is selected from the group consisting of polypeptides as shown in SEQ ID NO.2 or SEQ ID NO.4,
YLGASVPSPDPLEPTREQCELNPACDELSDQYGLKTAYKRIYGITI SEQ ID No.2；
YLYQWLGAPVPYPDPLEPREVCELNPDCDELADHIGFQEAYRRFYGPV SEQ ID No.4。
the invention also provides a derivative of the polypeptide targeting the brain tumor, wherein the derivative is a product obtained by modifying the tail end or the side chain of the polypeptide or a product obtained by modifying the polypeptide by an isotope label;
the product obtained by modification is selected from a product obtained by fluorescent group modification, a product obtained by phosphorylation modification, a product obtained by cyclization modification based on disulfide bond, a product obtained by biotin labeling modification, a product obtained by photosensitizer modification, a product obtained by azide modification, a product obtained by PEG modification, a product obtained by methylation modification, a product obtained by fluorescence quenching group modification, a product obtained by protein coupling modification, or a product obtained by small molecular compound modification;
the polypeptide is selected from the group consisting of a metabolin (Metabolin) or Osteocalcin (Osteocalcin).
Further, the metabolite is selected from the polypeptide shown as SEQ ID NO.1 or SEQ ID NO.3,
YLGASVPSPDPLEPT SEQ ID No.1；
YLYQWLGAPVPYPDPLEPR SEQ ID No.3。
further, osteocalcin is selected from the group consisting of polypeptides as shown in SEQ ID NO.2 or SEQ ID NO.4,
YLGASVPSPDPLEPTREQCELNPACDELSDQYGLKTAYKRIYGITI SEQ ID No.2；
YLYQWLGAPVPYPDPLEPREVCELNPDCDELADHIGFQEAYRRFYGPV SEQ ID No.4。
further, the modification of the terminal is selected from the group consisting of acetylation modification of the N-terminal of the polypeptide and amination modification of the C-terminal.
Further, the modification of the side chain is selected from the group consisting of modifications on the amino acid side chain R group in the polypeptide.
Further, the fluorescent dye used for the modification of the fluorescent group is selected from FITC, Rhodamine, Cy3, Cy5, Cy5.5, Cy7 and ICG, and the modification can be used for fluorescence detection.
Further, the phosphorylation modification is selected from one or more of p-Ser, p-Thr and p-Tyr.
Further, a label of said biotin selected from the group consisting of D-biotin, biotin hydrazide, photosensitive biotin and biotin-dUTP.
Further, the photosensitizer is modified and can be used for preparing photosensitive preparations.
Further, the azide modification can be used for secondary ligation.
Further, the PEG modification can be used for preparing a drug carrier.
Further, the isotope used in the isotope labeling is selected from13C、14C、15N、2H、3H、18O、34S、36One or a combination of more of S.
In another aspect, the invention provides an application of the polypeptide derivative in preparing a drug or a detection reagent capable of crossing the blood brain barrier and targeting brain tumor.
In another aspect, the present invention provides a brain tumor targeting vector, wherein the surface of the vector is modified with the polypeptide of the present invention.
Further, the carrier is selected from liposome and nanoparticle.
Further, the carrier is loaded with an active ingredient.
The cross-blood brain barrier mediated polypeptide can be autonomously synthesized under the condition of a general chemical laboratory or industrially synthesized by a commercial reagent company, the polypeptide is synthesized by adopting a solid phase method, different amino acids on resin are directionally synthesized into amino acid chains through condensation reaction. The polypeptide derivative is obtained by labeling modification groups after the amino acids are connected.
In another aspect, the invention provides a drug targeting brain tumor, wherein the drug is a conjugate of the polypeptide or the derivative thereof and an active ingredient. The polypeptide and the derivatives thereof can be combined on a diagnosis and/or treatment carrier by an organic chemistry method to play an application value on the basis of mediating the function of crossing a blood brain barrier.
The invention further provides a polypeptide probe targeting brain tumor, wherein the polypeptide probe is prepared by coupling the polypeptide or the derivative thereof with fluorescent dye through organic chemical reaction.
Further, the fluorescent dye is selected from dyes having a fluorescent group in a near infrared region, preferably, the dyes having a fluorescent group in a near infrared region are selected from Cy5, Cy7 and ICG.
In the present invention, the brain tumor is selected from glioma, medulloblastoma, ependymoma, brain metastasis, meningioma, sphenoid area tumor, acoustic neuroma, epidermoid cyst and dermato-like cyst.
Further, the brain tumor is in the cerebral cortex.
The invention has the beneficial effects that:
(1) the mediated polypeptide provided by the invention can automatically cross blood brain barrier and target brain tumor.
(2) The mediated polypeptide provided by the invention can be used as a modified polypeptide to enhance the targeting and the therapeutic property of a medicament or a medicament carrier to brain tumor.
(3) The mediated polypeptide provided by the invention is easy to synthesize and modify, and has low cost, so that the application prospect is wide.
(4) The multi-element derivative candidate polypeptide provided by the invention provides a wide preparation strategy of diagnosis and treatment compounds or medicines for practical application.
(5) The polypeptide molecule provided by the invention is suitable for the application of human brain medicine mediation due to the sequence specificity, and is also suitable for being used as a research tool in brain disease modeling experimental animals.
Drawings
FIG. 1 is a graph showing the effect of targeting a brain tumor in example 3 of the present invention. The figure shows the fluorescence signal distribution and results of 4 groups of mice in example 3.
Detailed Description
For a better understanding of the present invention, the following examples are provided to illustrate the present invention, but the present invention is not limited to the following examples.
Example 1: preparation of the polypeptide sequence
Adopts an artificial synthesis method to synthesize a polypeptide sequence crossing the blood brain barrier,
the polypeptide sequence is as follows:
YLGASVPSPDPLEPT SEQ ID No.1；
YLGASVPSPDPLEPTREQCELNPACDELSDQYGLKTAYKRIYGITI SEQ ID No.2；
YLYQWLGAPVPYPDPLEPR SEQ ID No.3；
YLYQWLGAPVPYPDPLEPREVCELNPDCDELADHIGFQEAYRRFYGPV SEQ IDNo.4。
the polypeptide is synthesized by conventional solid phase synthesis or liquid phase synthesis. The solid-phase synthesis polypeptide method comprises the steps of reacting from C-terminal amino acid to N-terminal, performing resin activation, amino acid linkage, elution protection, detection and the like, completing amino acid linkage one by one, then precipitating and centrifuging by using excessive ethyl ether, performing HPLC (high performance liquid chromatography) purification on crude peptide, performing mass spectrometry, and performing quick-cooling and freeze-drying in liquid nitrogen for later use.
Wherein SEQ ID NO.1 is murine metabolizing element, SEQ ID NO.2 is murine osteocalcin, SEQ ID NO.3 is human metabolizing element, and SEQ ID NO.4 is human osteocalcin.
Example 2: preparation of polypeptide Probe
This example provides a polypeptide probe that uses the polypeptide prepared in example 1 to bind ICG by an organic chemical reaction.
The specific method is purchase or synthesis, in this example, the probe preparation is completed by connecting the polypeptide and ICG by click chemistry, wherein the linker is general DBCO. ICG with an activating functional group comprising an amino NH group2Carboxyl group COOH, activated lipid NHS, maleimide MAL, mercapto group SH, azide N3Alkyne ALK, and then coupled with the polypeptide prepared in example 1 to obtain the blood brain barrier crossing polypeptide ICG probe.
Example 3: brain tumor mouse modeling and targeting ability detection
After 3 days from transplantation of human U87 glioma into a cerebral cortex site of a mouse using an adult mouse by a cerebral positioning instrument, 100. mu.l of the polypeptide ICG probe (containing SEQ ID NO.1), the disordered polypeptide probe, the ICG solution (2mM) and PBS prepared in example 2 were injected into the tail vein of each mouse, and 24 hours after the injection, the detection was performed under a mouse imager.
The results are shown in FIG. 1, and it can be seen from the results of comparison of 4 groups that the polypeptide probe group (group A) exhibited a specific signal at the brain tumor site, while none of the other three groups (group S: scrambled polypeptide probes; group N: ICG solution group; PBS group) exhibited a fluorescent signal at the brain. The experimental results show that the polypeptide probe can achieve the effect of targeting brain tumor across the blood brain barrier.
In conclusion, the mediating polypeptides provided herein can be used for brain tumor targeting purposes.
The above description is only a specific embodiment of the present invention, and not all embodiments, and any equivalent modifications of the technical solutions of the present invention, which are made by those skilled in the art through reading the present specification, are covered by the claims of the present invention.
SEQUENCE LISTING
<110> Shenzhen advanced technology research institute, Shenzhen university of science institute of China (Shen)
<120> polypeptide targeting brain tumor, and derivatives and applications thereof
<130> CP121011266C
<160> 4
<170> PatentIn version 3.3
<210> 1
<211> 15
<212> PRT
<213> Artificial sequence
<400> 1
Tyr Leu Gly Ala Ser Val Pro Ser Pro Asp Pro Leu Glu Pro Thr
1 5 10 15
<210> 2
<211> 46
<212> PRT
<213> Artificial sequence
<400> 2
Tyr Leu Gly Ala Ser Val Pro Ser Pro Asp Pro Leu Glu Pro Thr Arg
1 5 10 15
Glu Gln Cys Glu Leu Asn Pro Ala Cys Asp Glu Leu Ser Asp Gln Tyr
20 25 30
Gly Leu Lys Thr Ala Tyr Lys Arg Ile Tyr Gly Ile Thr Ile
35 40 45
<210> 3
<211> 19
<212> PRT
<213> Artificial sequence
<400> 3
Tyr Leu Tyr Gln Trp Leu Gly Ala Pro Val Pro Tyr Pro Asp Pro Leu
1 5 10 15
Glu Pro Arg
<210> 4
<211> 48
<212> PRT
<213> Artificial sequence
<400> 4
Tyr Leu Tyr Gln Trp Leu Gly Ala Pro Val Pro Tyr Pro Asp Pro Leu
1 5 10 15
Glu Pro Arg Glu Val Cys Glu Leu Asn Pro Asp Cys Asp Glu Leu Ala
20 25 30
Asp His Ile Gly Phe Gln Glu Ala Tyr Arg Arg Phe Tyr Gly Pro Val
35 40 45
Claims (10)
1. The use of a polypeptide in the preparation of a medicament or detection reagent targeting brain tumors; it is characterized in that the preparation method is characterized in that,
the polypeptide is selected from the group consisting of a metabolin (Metabolin) or Osteocalcin (Osteocalcin);
preferably, the metabolite is selected from the group consisting of the polypeptides shown in SEQ ID NO.1 or SEQ ID NO.3,
YLGASVPSPDPLEPT SEQ ID No.1；
YLYQWLGAPVPYPDPLEPR SEQ ID No.3；
preferably, osteocalcin is selected from the group consisting of the polypeptides as shown in SEQ ID NO.2 or SEQ ID NO.4,
YLGASVPSPDPLEPTREQCELNPACDELSDQYGLKTAYKRIYGITI SEQ ID No.2；
YLYQWLGAPVPYPDPLEPREVCELNPDCDELADHIGFQEAYRRFYGPV SEQ ID No.4。
2. use according to claim 1,
the brain tumor is selected from glioma, medulloblastoma, ependymoma, brain metastasis, meningioma, sphenoid area tumor, acoustic neuroma, epidermoid cyst and dermatocystoid cyst;
preferably, the brain tumor is in the cerebral cortex.
3. A polypeptide derivative that autonomously crosses the blood-brain barrier and targets brain tumors,
the polypeptide derivative is a product obtained by modifying the tail end or the side chain of the polypeptide or a product obtained by isotopic label modification;
the product obtained by modification is selected from a product obtained by fluorescent group modification, a product obtained by phosphorylation modification, a product obtained by cyclization modification based on disulfide bond, a product obtained by biotin labeling modification, a product obtained by photosensitizer modification, a product obtained by azide modification, a product obtained by PEG modification, a product obtained by methylation modification, a product obtained by fluorescence quenching group modification, a product obtained by protein coupling modification, or a product obtained by small molecular compound modification;
the polypeptide is selected from the group consisting of a metabolin (Metabolin) or Osteocalcin (Osteocalcin);
preferably, the metabolite is selected from the group consisting of the polypeptides shown in SEQ ID NO.1 or SEQ ID NO.3,
YLGASVPSPDPLEPT SEQ ID No.1；
YLYQWLGAPVPYPDPLEPR SEQ ID No.3；
preferably, osteocalcin is selected from the group consisting of the polypeptides as shown in SEQ ID NO.2 or SEQ ID NO.4,
YLGASVPSPDPLEPTREQCELNPACDELSDQYGLKTAYKRIYGITI SEQ ID No.2；
YLYQWLGAPVPYPDPLEPREVCELNPDCDELADHIGFQEAYRRFYGPV SEQ ID No.4。
4. the polypeptide derivative that autonomously crosses the blood-brain barrier and targets a brain tumor according to claim 3, wherein the modification at the terminal is selected from the group consisting of an acetylation modification at the N-terminus and an amination modification at the C-terminus of the polypeptide;
the modification of the side chain is selected from the group consisting of modification on the amino acid side chain R group in the polypeptide;
the fluorescent dye used for modifying the fluorescent group is selected from FITC, Rhodamine, Cy3, Cy5, Cy5.5, Cy7 and ICG, and the modification can be used for fluorescence detection;
the phosphorylation modification is selected from one or more of p-Ser, p-Thr and p-Tyr;
a label for said biotin selected from the group consisting of D-biotin, biotin hydrazide, photostable biotin and biotin-dUTP;
the photosensitizer is modified and can be used for preparing photosensitive preparations;
the azide modification can be used for secondary connection reaction;
the PEG modification can be used for preparing a drug carrier;
the isotope used in the isotope labeling is selected from13C、14C、15N、2H、3H、18O、34S、36One or a combination of more of S.
5. Use of a polypeptide derivative according to claim 3 or 4 for the manufacture of a medicament or a detection reagent capable of targeting a brain tumour across the blood-brain barrier.
6. The use of claim 5, wherein the brain tumor is selected from the group consisting of glioma, medulloblastoma, ependymoma, brain metastasis, meningioma, sphenoid area tumor, acoustic neuroma, epidermoid cyst, dermato-like cyst;
preferably, the brain tumor is in the cerebral cortex.
7. A brain tumor targeting carrier, wherein the surface of the carrier is modified with polypeptide; wherein the polypeptide is selected from the group consisting of a metabolin (Metabolin) and Osteocalcin (Osteocalcin);
preferably, the metabolite is selected from the group consisting of the polypeptides shown in SEQ ID NO.1 or SEQ ID NO.3,
YLGASVPSPDPLEPT SEQ ID No.1；
YLYQWLGAPVPYPDPLEPR SEQ ID No.3；
preferably, osteocalcin is selected from the group consisting of the polypeptides as shown in SEQ ID NO.2 or SEQ ID NO.4,
YLGASVPSPDPLEPTREQCELNPACDELSDQYGLKTAYKRIYGITI SEQ ID No.2；
YLYQWLGAPVPYPDPLEPREVCELNPDCDELADHIGFQEAYRRFYGPV SEQ ID No.4。
8. the vector according to claim 7, wherein the vector is selected from the group consisting of liposomes, nanoparticles;
preferably, the carrier is loaded with an active ingredient.
9. A polypeptide probe targeting brain tumor is characterized in that the polypeptide probe is polypeptide or a derivative thereof and is prepared by coupling with fluorescent dye through organic chemical reaction;
the polypeptide is selected from the group consisting of a metabolin (Metabolin) or Osteocalcin (Osteocalcin); the metabolin is selected from the polypeptide shown in SEQ ID NO.1 or SEQ ID NO.3,
YLGASVPSPDPLEPT SEQ ID No.1；
YLYQWLGAPVPYPDPLEPR SEQ ID No.3；
osteocalcin is selected from the polypeptide shown in SEQ ID NO.2 or SEQ ID NO.4,
YLGASVPSPDPLEPTREQCELNPACDELSDQYGLKTAYKRIYGITI SEQ ID No.2；
YLYQWLGAPVPYPDPLEPREVCELNPDCDELADHIGFQEAYRRFYGPV SEQ ID No.4；
preferably, the fluorescent dye is selected from dyes having a fluorophore in the near infrared region, more preferably, the dye having a fluorophore in the near infrared region is selected from Cy5, Cy7, ICG.
10. A drug targeting brain tumor, wherein the drug is a conjugate of the polypeptide or the derivative thereof and an active ingredient;
the polypeptide is selected from the group consisting of a metabolin (Metabolin) or Osteocalcin (Osteocalcin); the metabolin is selected from the polypeptide shown in SEQ ID NO.1 or SEQ ID NO.3,
YLGASVPSPDPLEPT SEQ ID No.1；
YLYQWLGAPVPYPDPLEPR SEQ ID No.3；
osteocalcin is selected from the polypeptide shown in SEQ ID NO.2 or SEQ ID NO.4,
YLGASVPSPDPLEPTREQCELNPACDELSDQYGLKTAYKRIYGITI SEQ ID No.2；
YLYQWLGAPVPYPDPLEPREVCELNPDCDELADHIGFQEAYRRFYGPV SEQ ID No.4；
the active ingredient is an anti-tumor ingredient.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111488756.1A CN114306630A (en) | 2021-12-07 | 2021-12-07 | Polypeptide targeting brain tumor, derivative and application thereof |
| PCT/CN2022/137005 WO2023104048A1 (en) | 2021-12-07 | 2022-12-06 | Brain tumor-targeting polypeptide, derivative thereof and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111488756.1A CN114306630A (en) | 2021-12-07 | 2021-12-07 | Polypeptide targeting brain tumor, derivative and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114306630A true CN114306630A (en) | 2022-04-12 |
Family
ID=81048613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111488756.1A Pending CN114306630A (en) | 2021-12-07 | 2021-12-07 | Polypeptide targeting brain tumor, derivative and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114306630A (en) |
| WO (1) | WO2023104048A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114748610A (en) * | 2022-04-13 | 2022-07-15 | 中国科学院深圳先进技术研究院 | Application of osteocalcin in preparing anti-inflammatory medicine |
| WO2023104048A1 (en) * | 2021-12-07 | 2023-06-15 | 深圳先进技术研究院 | Brain tumor-targeting polypeptide, derivative thereof and application thereof |
| WO2023213141A1 (en) * | 2022-05-05 | 2023-11-09 | 中国科学院深圳先进技术研究院 | Ovary-targeting polypeptide, and derivative and use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107011427A (en) * | 2017-03-16 | 2017-08-04 | 深圳先进技术研究院 | Adjust polypeptide of energetic supersession and application thereof |
| CN107698682A (en) * | 2010-05-03 | 2018-02-16 | 百时美施贵宝公司 | Seralbumin binding molecule |
| CN108324927A (en) * | 2018-05-04 | 2018-07-27 | 上海市内分泌代谢病研究所 | Osteocalcin prepares the purposes for the treatment of Parkinsonian drugs |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114306630A (en) * | 2021-12-07 | 2022-04-12 | 深圳先进技术研究院 | Polypeptide targeting brain tumor, derivative and application thereof |
-
2021
- 2021-12-07 CN CN202111488756.1A patent/CN114306630A/en active Pending
-
2022
- 2022-12-06 WO PCT/CN2022/137005 patent/WO2023104048A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107698682A (en) * | 2010-05-03 | 2018-02-16 | 百时美施贵宝公司 | Seralbumin binding molecule |
| CN107011427A (en) * | 2017-03-16 | 2017-08-04 | 深圳先进技术研究院 | Adjust polypeptide of energetic supersession and application thereof |
| CN108324927A (en) * | 2018-05-04 | 2018-07-27 | 上海市内分泌代谢病研究所 | Osteocalcin prepares the purposes for the treatment of Parkinsonian drugs |
Non-Patent Citations (1)
| Title |
|---|
| NINGNING LI等: "Inhibition of GPR158 by microRNA-449a suppresses neural lineage of glioma stem/progenitor cells and correlates with higher glioma grades", 《ONCOGENE》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023104048A1 (en) * | 2021-12-07 | 2023-06-15 | 深圳先进技术研究院 | Brain tumor-targeting polypeptide, derivative thereof and application thereof |
| CN114748610A (en) * | 2022-04-13 | 2022-07-15 | 中国科学院深圳先进技术研究院 | Application of osteocalcin in preparing anti-inflammatory medicine |
| WO2023213141A1 (en) * | 2022-05-05 | 2023-11-09 | 中国科学院深圳先进技术研究院 | Ovary-targeting polypeptide, and derivative and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023104048A1 (en) | 2023-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114306630A (en) | Polypeptide targeting brain tumor, derivative and application thereof | |
| KR101151805B1 (en) | Bipodal Peptide Binder | |
| CN114288414A (en) | Polypeptide crossing blood brain barrier, derivative and application thereof | |
| US7807778B2 (en) | Cysteine-containing peptide tag for site-specific conjugation of proteins | |
| JP5677454B2 (en) | Bidentate peptide binder for intracellular target binding | |
| WO2020103961A2 (en) | Brain tumor-targeting peptide and application thereof | |
| JP5677453B2 (en) | BPB based cargo transport system | |
| JP2015535523A (en) | Aprotinin-derived polypeptide-antibody conjugate | |
| US20030186890A1 (en) | Amphipathic linear peptides and formulations containing said peptides | |
| JP7456676B2 (en) | Novel cell-penetrating peptides and their uses | |
| CN110420334A (en) | A kind of method of drug conjugate and raising drug molecule half-life period | |
| US20230406927A1 (en) | Masked single-domain antibodies and methods thereof | |
| JP2023507884A (en) | Drugs with extended half-lives and libraries thereof, and methods of manufacture and uses | |
| TWI602577B (en) | Dual targeting drug carrier and application thereof | |
| EP1809332A2 (en) | Compositions for multi-step delivery of hot-spots radiation to cancer cells | |
| CN108699164B (en) | Dual target drug carrier | |
| CN113952467A (en) | Endometriosis molecular diagnosis and treatment preparation and preparation method and application thereof | |
| CN113956331A (en) | Ectopic endometrium recognition polypeptide and derivative and application thereof | |
| CN117777237A (en) | BCMA-targeted polypeptide and application thereof | |
| CN116804049A (en) | Ferritin tracer polypeptide conjugates and uses thereof | |
| CN117815402A (en) | Coupling medicine of targeting STAT3 protein and application thereof | |
| TW202321274A (en) | Human transferrin receptor-binding peptide | |
| CN111574589A (en) | Small molecule polypeptide for targeting integrin alpha 3 beta 1 receptor and preparation method and application thereof | |
| MEARES | NEWER BIOCONJUGATION METHODS | |
| CN110156897A (en) | A kind of fusion protein and application thereof comprising TRAIL and IgG binding structural domain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |